Navigation Links
MedinCell to Explore Controlled-Release Drug Delivery Partnerships at the World Animal Health Congress
Date:12/2/2011

SAN DIEGO and MONTPELLIER, France, Dec. 2, 2011 /PRNewswire/ -- MedinCell, a leading developer of low-cost, controlled-release drug delivery technology, will be exploring partnerships for key companion and food animal markets with industry leaders at the Terrapinn World Animal Health Congress in Kansas City (December 6-8, 2011).

"MedinCell's biodegradable polymer technology offers exceptional control over the duration of drug release, thereby making small molecules—and even peptides—cost effective for the companion and food animal markets," said Dr. Alexandre Melin, Director of Animal Health for MedinCell. "Our platform's inherent flexibility enables us to design single-injection products that release drug molecules systemically over just a few days, or across multiple-months. With some APIs, we can achieve therapeutic plasma levels throughout an entire year," Dr. Melin (alexandre.melin@medincell.eu) continued.

Dr. Anh Nguyen, MedinCell Founder and CEO, explained, "MedinCell has experience formulating molecules for chemocastration, diabetes, pain control and parasitology. Our MedinGel™ technology brings a strong environmental benefit to animal health brands by reducing the required drug cargo, and therefore the amount of API cleared by the animals. This can also lead to a substantial reduction in product cost for animal health companies."

"MedinCell recognizes that the demand for protein production is increasing, and requires novel approaches to support the growing global population," commented Dr. Melin, who welcomes meeting requests at the World Animal Health Congress to discuss controlled-release strategies. "We look forward to designing novel products that improve product efficiency and animal treatment for the food animal industry," concluded Dr. Melin.

About MedinCell

MedinCell's patent-pending drug delivery technology, MedinGel, entraps drug molecules in a polymer matrix after injected. By limiting the initial drug burst, MedinCell can design formulations that extend release duration. With MedinGel, substantially less API cargo is required than for products designed for oral administration, which is a pivotal consideration for cost-sensitive markets such as animal health. MedinCell SA is headquartered in Montpellier, France, and recently launched formulation and R&D activities at its US subsidiary, MedinCell Corporation, in San Diego, California. Contact information for both facilities is available at www.medincell.com.

Information on the Terrapinn World Animal Health Congress is available online: http://www.terrapinn.com/2011/world-animal-health-congress/index.stm

 

 

CONTACT:  Chris Hoover, MedinCell Corporation, +1-858-216-4573, chris.hoover@medincell.com


'/>"/>
SOURCE MedinCell
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
4. 42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases
5. Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes
6. Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis
7. Webinar to Explore FDA Draft REMS Guidance and Its Implications for Lifecycle Management
8. New Manhattan Research Report Explores the Growing Consumer Demand for Online Health Video and How Pharma Marketers Can Leverage this Format
9. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
10. Advanced Life Sciences to Explore Strategic Alternatives to Maximize Shareholder Value
11. Retrospective Analysis Explores LYSTEDA®s Ability to Reduce Sleep Interruptions in Women With Cyclic Heavy Menstrual Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Eyevensys, a private biotechnology company developing its ... that enables the safe, local, sustained production of therapeutic ... of ophthalmic diseases, announces it has received approval from ... to advance its technology into clinical development. ... The EyeCET platform uses ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology:
(Date:4/21/2017)... IL (PRWEB) , ... April 21, 2017 , ... Chicago ... revolutionize the removal of osteoma. An osteoma is a benign bony lump located on ... the eye and can cause difficulties with sight and pain. Dr. Shah has discovered ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its ... that the full potential of specialty and orphan brands can only be achieved when ... , “The Unifying Effect is at the heart of a true partnership between our ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Hong Kong Polytechnic University ... printing facility among higher education institutions in Hong Kong to support teaching, learning and ... the range and quantity of facilities in Hong Kong. , With an area ...
(Date:4/21/2017)... ... 2017 , ... Airway Management, the medical device manufacturer of ... and well renowned Asian distributor, Discovery Sleep. The agreement involves the ... and will stabilize and strengthen Airway’s presence with a dedicated, reputable medical device ...
(Date:4/21/2017)... ... April 21, 2017 , ... Providing for loved ones before one’s passing is ... where to even begin. “Now more than ever there are some questions that are ... and your family,” said attorney Lisa Edgar Dickman, founder of the Law Offices of ...
Breaking Medicine News(10 mins):